Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
Wüthrich
R P
RP
Division of Nephrology, University Hospital, Zürich, Switzerland.
Weinreich
T
T
Schwarzkopf
A K
AK
Candinas
D
D
Binswanger
U
U
D001379:Azathioprine / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000493:pharmacokinetics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012086:Reoperation; D015996:Survival Rate; D013557:Switzerland; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D009173:Mycophenolic Acid; D001379:Azathioprine; D011241:Prednisone